Last reviewed · How we verify

Sonidegib Phosphate Capsules

Jemincare · FDA-approved active Small molecule Under review

Sonidegib Phosphate Capsules is a Hedgehog pathway inhibitor Small molecule drug developed by Jemincare. It is currently FDA-approved for Locally advanced basal cell carcinoma (laBCC).

Sonidegib is a Hedgehog pathway inhibitor that blocks Smoothened (SMO) signaling to suppress aberrant cell proliferation driven by Hedgehog pathway activation.

Sonidegib Phosphate Capsules are used to treat locally advanced basal cell carcinoma (BCC). They work by inhibiting the protein smoothened, a component of the Hedgehog signaling pathway.

At a glance

Generic nameSonidegib Phosphate Capsules
SponsorJemincare
Drug classHedgehog pathway inhibitor
TargetSmoothened (SMO)
ModalitySmall molecule
Therapeutic areaOncology
PhaseFDA-approved

Mechanism of action

Sonidegib selectively inhibits Smoothened, a key transmembrane protein in the Hedgehog signaling cascade. By blocking SMO, it prevents downstream activation of Gli transcription factors, thereby suppressing the proliferation of cells dependent on Hedgehog pathway signaling. This mechanism is particularly effective in tumors with constitutive Hedgehog pathway activation, such as basal cell carcinoma.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Sonidegib Phosphate Capsules

What is Sonidegib Phosphate Capsules?

Sonidegib Phosphate Capsules is a Hedgehog pathway inhibitor drug developed by Jemincare, indicated for Locally advanced basal cell carcinoma (laBCC).

How does Sonidegib Phosphate Capsules work?

Sonidegib is a Hedgehog pathway inhibitor that blocks Smoothened (SMO) signaling to suppress aberrant cell proliferation driven by Hedgehog pathway activation.

What is Sonidegib Phosphate Capsules used for?

Sonidegib Phosphate Capsules is indicated for Locally advanced basal cell carcinoma (laBCC).

Who makes Sonidegib Phosphate Capsules?

Sonidegib Phosphate Capsules is developed and marketed by Jemincare (see full Jemincare pipeline at /company/jemincare).

What drug class is Sonidegib Phosphate Capsules in?

Sonidegib Phosphate Capsules belongs to the Hedgehog pathway inhibitor class. See all Hedgehog pathway inhibitor drugs at /class/hedgehog-pathway-inhibitor.

What development phase is Sonidegib Phosphate Capsules in?

Sonidegib Phosphate Capsules is FDA-approved (marketed).

What are the side effects of Sonidegib Phosphate Capsules?

Common side effects of Sonidegib Phosphate Capsules include Muscle spasms, Alopecia, Dysgeusia (taste disturbance), Fatigue, Nausea, Diarrhea.

What does Sonidegib Phosphate Capsules target?

Sonidegib Phosphate Capsules targets Smoothened (SMO) and is a Hedgehog pathway inhibitor.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing